JCyte signs ex-US licensing deal with Santen for retinal disease therapy

This article was originally published here

According to jCyte, treatment with jCell is a minimally-invasive intravitreal injection, which can be carried out in an ophthalmologist’s office with topical anesthetic. The entire procedure is said

The post JCyte signs ex-US licensing deal with Santen for retinal disease therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply